TXG · 10x Genomics, Inc. · Metrics
$51.80
-5.58 (-9.72%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$6.81B
Shares
131.53M
Volume · Nov 20
3.23M
Avg daily vol (3M)
3.36M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
TXG metrics
89 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$51.80
Market cap
$6.81B
Price action
23 metricsPrice change (1W)
-11.0%
Price change (30D)
-25.7%
Price change (3M)
-20.5%
Price change (6M)
+118.8%
Price change (YTD)
+217.6%
Price change (1Y)
+214.7%
Trailing year
Price change (5Y)
-65.5%
52-week high
$97.74
52-week low
$15.46
Change from 52-week high
-47.0%
Change from 52-week low
+235.1%
Annualized volatility
76.9%
Annualized volatility (3M)
87.7%
Implied volatility (30D)
87.2%
IV rank (1Y)
36.3
IV percentile (1Y)
54.9
Beta
2.5
RSI (14D)
35.0
Price vs SMA 50
-28.9%
Price vs SMA 200
+19.1%
Avg volume (3M)
3.36M
Relative volume
1.0
Average dollar volume
$241.07M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
131.53M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.0×
reciprocal yield 9.1%
P / book
8.1
reciprocal yield 12.3%
FCF yield
1.4%
TTM · current market cap
Buyback yield
—
P / FCF
72.7
reciprocal yield 1.4%
P / operating cash flow
68.3
reciprocal yield 1.5%
Earnings yield
-1.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
43.2×
reciprocal yield 2.3%
EV / revenue historical average (5Y)
43.2×
reciprocal yield 2.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-11-05
Profitability
9 metricsGross margin
71.9%
Operating margin
-11.7%
Trailing 12 months
Net margin
-10.8%
Gross profit (TTM)
$444.65M
Operating profit (TTM)
−$72.20M
Net income (TTM)
−$67.08M
Trailing 12 months
Diluted EPS (TTM)
$-0.52
FCF margin
15.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+1.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$618.58M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.2%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+16.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-8.0%
Return on assets
-6.3%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
−$33.01M
Free cash flow (TTM)
$93.77M
Quick ratio
4.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$526.19M
Total assets
$1.06B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$99.70M
Capital expenditures (TTM)
$5.93M
R&D (TTM)
$222.54M
SG&A (TTM)
$297.71M
Stock compensation (TTM)
$96.57M
R&D / revenue
36.0%
Stock compensation / revenue
15.6%
Ownership (13F)
9 metrics13F filers
494
13F filer change QoQ
+98
Institutional ownership
99.0%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.4%
Holder tenure
17.9
Price vs estimated holder cost
+144.7%
Ownership (registered funds)
1 metricsIndex-fund ownership
15.7%
Short interest
3 metricsShort interest
9.5%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
−$12.61M
Insider-sentiment score
11 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1770787
CUSIP
88025U109
13F (30d)
482 filings
441 filers
Visit website
Investor relations